Exagen IncXGN
Price$7.89Intrinsic value$3.8451% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $71.1M+27.8% YoYTTM through 30 Jun 2026
Net Income -$18.9MTTM through 30 Jun 2026
Free Cash Flow -$7.6MTTM through 30 Jun 2026

Margins

Current
Gross Margin59.0%
EBITDA Margin-15.2%
Operating Margin-19.7%
Net Margin-26.6%

Returns

-154.9%ROE
-36.4%ROA

Balance Sheet Health

Debt / Equity1.59x
Current Ratio3.18x
Net Debt$1.4M
Cash & Equivalents$24.6M

Quality Metrics

Altman Z-Score-4.26
Piotroski F-Score2 / 9
FCF Margin-10.7%
Rule of 40-9.9
Earnings-Beat Rate25.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $66.6M
Diluted EPS-$0.82TTM
'20'21'22'23'24'25
FY2025: $-0.93

Dividend

No dividend

Capital Allocation

R&D Spend$6.5M
Capex Intensity1.5%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.